Does Cholesterol Reduction with Cholestyramine Prevent Coronary Heart Disease among Individuals with Prehypertension?

REFERENCES

• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003; 289: 2560–72
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004; 164: 2126–34
   PubMed Web of Science ®Google Scholar
• Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13
   PubMed Web of Science ®Google Scholar
• Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 119: 133–41
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases?. Stroke 2005; 36: 1859–63
   PubMed Web of Science ®Google Scholar
• Liszka HA, Mainous AG, III, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294–9
   PubMed Web of Science ®Google Scholar
• Russell LB, Valiyeva E, Carson JL. Effects of prehypertension on admissions and deaths: a simulation. Arch Intern Med 2004; 164: 2119–24
   PubMed Web of Science ®Google Scholar
• Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005; 46: 280–86
   PubMed Web of Science ®Google Scholar
• Greenlund KJ, Croft JB, Mensah GA. Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch Intern Med 2004; 164: 2113–18
   PubMed Web of Science ®Google Scholar
• Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, III, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM. OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. J Am Med Assoc 2005; 294: 2455–64
   PubMed Web of Science ®Google Scholar
• Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, Lin PH, Champagne C, Harsha DW, Svetkey LP, Ard J, Brantley PJ, Proschan MA, Erlinger TP, Appel LJ. PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144: 485–95
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Jr, Messerli FH, Oparil S, Schork MA. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354(20)1685–97
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial. Results I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351–64
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial: Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984; 251: 365–74
   PubMed Web of Science ®Google Scholar
• The coronary primary prevention trial. Design and implementation: the Lipid Research Clinics Program. J Chronic Dis 1979; 32: 609–31
   PubMedGoogle Scholar
• Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality. Arch Intern Med 2005; 165: 725–30
   PubMed Web of Science ®Google Scholar
• Bucher HC, Griffith LE, Guyatt GH. Systemic review on the risk of benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187–95
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–22
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. J Am Med Assoc 2002; 288: 2998–3007
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001; 286: 64–70
   PubMed Web of Science ®Google Scholar
• Denke MA. Diet, lifestyle, and nonstatin trials: review of time to benefit. Am J Cardiol 2005; 96: 3F–10F
   PubMed Web of Science ®Google Scholar
• Daviglus ML, Liu K. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 2004; 164: 2086–7
   PubMed Web of Science ®Google Scholar
• Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens 2005; 18: 1249–57
   PubMed Web of Science ®Google Scholar